Answer
Stopping anticoagulant activity exposes the patient's existing clotting risk. Andexanet alfa also inhibits tissue factor pathway inhibitor, which can increase thrombin generation.
Sources for this answer
- Ondexxya 200 mg powder for solution for infusionemc · SmPC Current selected SmPC · Version 17